Adenosine inhibits IL-12 and TNF-α production via adenosine A(2a) receptor-dependent and independent mechanism

FASEB Journal

Volumn 14, Issue 13, 2000, Pages 2065-2074

  Haskó, György ^a,b   Kuhel, David G ^a   Chen, Jiang Fan ^c   Schwarzschild, Michael A ^c   Deitch, Edwin A ^b   Mabley, Jon G ^a   Marton, Anita ^a   Szabó, Csaba ^a  

^a INOTEK CORPORATION   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cytokines; Inflammation; Inflammatory mediators; T lymphocytes

Indexed keywords

2 CHLORO 6 N CYCLOPENTYLADENOSINE; 2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 3,7 DIMETHYL 1 PROPARGYLXANTHINE; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; 8 (2 AMINO 4 CHLOROPHENYL) 1,3 DIPROPYLXANTHINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; 9 CHLORO 2 (2 FURANYL) 5 PHENYLACETYLAMINO (1,2,4) TRIAZOLO[1,5 C]QUINAZOLINE; 9 CHLORO 2 (2 FURYL) 5 PHENYLACETYLAMINO 1,2,4 TRIAZOLO[1,5 C]QUINAZOLINE; ADENOSINE; ADENOSINE A2 RECEPTOR; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; DIPYRIDAMOLE; INTERLEUKIN 10; INTERLEUKIN 12; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P40; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ENZYME ACTIVATION; INFLAMMATION; MACROPHAGE; MALE; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; PERITONEUM CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR AFFINITY; RECEPTOR DOWN REGULATION;

ANIMALIA;

EID: 0033820684     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.99-0508com     Document Type: Article

References (56)

1. The interleukin-12/interleukin-12-receptor system: Role in normal and pathologic immune responses
2. Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity
3. Impairment of mycobacterial immunity in human interleukin-12 deficiency
4. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients
5. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12
6. Antibodies to intedeukin 12 abrogate established experimental colitis in mice
7. Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice
8. Administration of interleukin 12 in combination with type II collagen induces severe arthritis in DBA/1 mice
9. Interleukin-12 is required for interferon-γ production and lethality in lipopolysaccharide-induced shock in mice
10. Interleukin 12, interferon gamma, and tumor necrosis factor alpha are the key cytokines of the generalized Shwartzman reaction
11. 1 adenosine receptors
12. Cloned adenosine A3 receptors: Pharmacological properties, species differences and receptor functions
13. Pharmacology of adenosine A(2A) receptors
14. IFN-γ up-regulates the A(2B) adenosine receptor expression in macrophages: A mechanisms of macrophage deactivation
15. 1 receptors
16. Insights into thymic purine metabolism and adenosine deaminase deficiency revealed by transgenic mice overexpressing ecto-5'-nucleotidase (CD73)
17. Adenosine receptors and modulation of natural killer cell activity by purine nucleosides
18. Differential regulatory effects of adenosine on cytokine release by activated human monocytes
19. Adenosine reduces cardiac TNF-α production and human myocardial injury following ischemia-reperfusion
20. Adenosine receptor agonists differentially regulate IL-10, TNF-α, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice
21. Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-α production and protect mice against endotoxin challenge
22. Stimulation of interleukin-6 secretion and gene transcription in primary astrocytes by adenosine
23. Role of A(2a) adenosine receptors in inflammation
24. Suppression of macrophage inflammatory protein (MIP)-1 alpha production and collagen-induced arthritis by adenosine receptor agonists
25. Adenosine increases interleukin 6 release and decreases tumor necrosis factor release from rat adrenal zona glomerulosa cells, ovarian cells, anterior pituitary cells, and peritoneal macrophages
26. Dysregulation of adenosine A1 receptor-mediated cytokine expression in peripheral blood mononuclear cells from multiple sclerosis patients
27. 4 synthesis in whole blood ex vivo
28. Purinergic regulation of bradykinin-induced plasma extravasation and adjuvant-induced arthritis in the rat
29. 3 adenosine receptors decreases IL-12, IFN-γ and nitric oxide production and prevents lethality in endotoxemic mice
30. Modulation of anti-Thy1 nephritis in the rat by adenine nucleotides: Evidence for an anti-inflammatory role for nucleotidases
31. Pharmacologic modulation of acute ocular inflammation. I. Adenosine
32. Adenosine, an endogenous anti-inflammatory agent
33. 2-purinergic receptors for extracellular ATP and other nucleotides
34. Regulation of cytokine and chemokine production by transmitters and co-transmitters of the autonomic nervous system
35. A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice
36. Prostaglandin-E2 is a potent inhibitor of human interleukin-12 production
37. Suppression of interleukin-12 production by phosphodiesterase inhibition in routine endotoxemia is interleukin-10 independent
38. 3 adenosine receptors: Protective vs. damaging effects identified using novel agonists and antagonists
39. Receptors for purines and pyrimidines
40. Neutrophil-derived 5'-adenosine monophosphate promotes endothelial barrier function via CD73-mediated conversion to adenosine and endothelial A(2b) receptor activation
41. Adenosine enhances IL-10 secretion by human monocytes
42. Signal transduction and transcription factors in rheumatic disease
43. Ischemia/reperfusion-induced IFN-γ up-regulation: Involvement of IL-12 and IL-18
44. Inhibition of TNF-α expression by adenosine: Role of A3 adenosine receptors
45. Endogenous adenosine curtails lipopolysaccharide-stimulated tumour necrosis factor synthesis
46. Inosine inhibits inflammatory cytokine production by a posttranscriptional mechanism and protects against endotoxin-induced shock
47. 6-(3-chlorobenzyl)-5'-N-methylcarboxamidoadenosine (CB-MECA) provides cardioprotection via K(ATP) channel activation
48. Properties and functions of interleukin-10
49. Role of CSBP/p38/RK stress kinase response in LPS and cytokine signaling mechanisms
50. MAPKAP kinase 2 is essential for LPS-induced TNF-α biosynthesis
51. Functional coupling of adenosine A2a receptor to inhibition of the mitogen-activated protein kinase cascade in Chinese hamster ovary cells
52. Role of p38 mitogen-activated protein kinase and extracellular signal-regulated protein kinase kinase in adenosine A(2B) receptor-mediated interleukin-8 production in human mast cells
53. The antiinflammatory effects of an adenosine kinase inhibitor are mediated by adenosine
54. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells
55. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites
56. Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFκB